Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Federal Trade Commission
Harvard Business School
Chubb
Fuji
Argus Health
Boehringer Ingelheim
Moodys
Queensland Health

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,074,644

« Back to Dashboard

Summary for Patent: 8,074,644
Title:Method of forming an aerosol for inhalation delivery
Abstract: The present invention relates to the inhalation delivery of aerosols containing small particles. Specifically, it relates to a method of forming an aerosol for use in inhalation therapy. In a method aspect of the present invention, a method of forming an aerosol for use in inhalation therapy is provided. The method involves the following steps: (a) heating a substrate coated with a composition comprising a drug at a rate greater than 1000.degree. C./s, thereby forming an vapor; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy. In another method aspect of the present invention, a method of forming an aerosol for use in inhalation therapy is provided. The method involves the following steps: (a) heating a substrate coated with a composition comprising a drug to form a vapor, wherein the coated composition is in the form of a film less than 10.mu. thick; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy. In another method aspect of the present invention, a method of forming an aerosol for use in inhalation therapy is provided. The method involves the following steps: (a) heating a substrate coated with a composition comprising a drug to form a vapor in less than 100 milliseconds, wherein the vapor has a mass greater than 0.1 mg; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy.
Inventor(s): Hale; Ron L. (Sandia Park, NM), Hodges; Craig C. (Walnut Creek, CA), Lloyd; Peter M. (Walnut Creek, CA), Mufson; Daniel (Napa, CA), Rogers; Daniel D. (Oakland, CA), Song; Soonho (Hillsborough, CA), Wensley; Martin J. (Los Gatos, CA), Myers; Daniel J. (Mountain View, CA), McKinney; Jeffrey A. (Lafayette, CA), Quintana; Reynaldo J. (Redwood City, CA), Rabinowitz; Joshua D. (Princeton, NJ)
Assignee: Alexza Pharmaceuticals, Inc. (Mountain View, CA)
Application Number:12/471,070
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,074,644

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Galen Uk ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,074,644

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,442,368 Delivery of stimulants through an inhalation route ➤ Subscribe
7,498,019 Delivery of compounds for the treatment of headache through an inhalation route ➤ Subscribe
7,449,175 Delivery of erectile dysfunction drugs through an inhalation route ➤ Subscribe
9,211,382 Drug condensation aerosols and kits ➤ Subscribe
7,018,621 Delivery of rizatriptan or zolmitriptan through an inhalation route ➤ Subscribe
9,440,034 Drug condensation aerosols and kits ➤ Subscribe
7,449,173 Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route ➤ Subscribe
6,737,042 Delivery of drug esters through an inhalation route ➤ Subscribe
7,465,435 Delivery of beta-blockers through an inhalation route ➤ Subscribe
6,759,029 Delivery of rizatriptan and zolmitriptan through an inhalation route ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,074,644

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 365548 ➤ Subscribe
Austria 401063 ➤ Subscribe
Austria 401064 ➤ Subscribe
Austria 404173 ➤ Subscribe
Austria 404184 ➤ Subscribe
Austria 406878 ➤ Subscribe
Austria 415155 ➤ Subscribe
Austria 418330 ➤ Subscribe
Austria 418971 ➤ Subscribe
Austria 425746 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Cipla
Daiichi Sankyo
Johnson and Johnson
Deloitte
Baxter
Fish and Richardson
Colorcon
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot